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Despite an estimated 84,000 deaths related to hepatitis C
virus (HCV) infection in Europe each year, no strategy to
respond to HCV is in place in the majority of European
countries according to two surveys published in BMC
[1-3]. Why is this so and does it matter?
The lack of public interest in this important threat to
public health is striking and probably explains the lack of
policy responses. Hepatitis is correctly described as the
silent epidemic in which patients carry the virus for
decades before a quarter succumb to liver failure or liver
cancer [4,5]. Most patients acquiring hepatitis C in recent
decades in Europe have been infected through injecting
drug use [6]. The disease therefore carries an important
stigma discouraging individuals from publicly acknowled-
ging their infection; this stigma probably also explains why
patient groups are conspicuously absent. Furthermore,
successful HCV treatment lacks “the Lazarus effect” seen
after successful treatment of HIV. By the time symptoms
of liver failure appear, HCV treatment has until recently
been unable to reverse the disease. Treatment regimens
have long been associated with considerable toxicity
limiting access to therapy due to medical, social and
structural reasons.
But this scenario is rapidly changing. A paradigm shift is
underway, with combinations of direct-acting antivirals
replacing interferon-based therapies [7]. Treating almost
every person with HCV regardless of liver disease stage,
viral genotype, past therapies or comorbidities is possible.
Hard-to-treat populations such as people who inject
drugs, HIV-coinfected individuals and patients with
psychiatric comorbidities will be much easier to treat with
high cure rates. However, per-patient treatment costs will
also increase and will be a challenge for national health
systems due to the expanding number of patients. This
will be a substantial challenge in particular for Southern
and Eastern Europe, including Russia, where HCV
prevalence and incidence rates are high. Even in western
European countries, however, the current pricing of
new direct-acting antivirals enabling interferon-free ther-
apy – such as sofosbuvir and simeprevir – is threatening
to affect healthcare budgets substantially. As a con-
sequence, access to this beneficial therapy will be sadly
limited due to conflicting economic interests.
For this reason, the lack of a strategy to fight HCV is a
matter of concern. In the meantime the high prices of the
new drugs may prove to have the paradoxical effect of
increasing public awareness of this disease, motivating
policy-makers to put in place good strategies for hepatitis
C prevention and treatment and bring down prices.
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